Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/Nab-Paclitaxel vs. mFOLFIRINOX in Borderline Resectable Pancreatic Cancer
NCT02241551Phase 2Terminated
- Start
- Dec 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) (2 arms). Primary endpoint: Safety and Efficacy of Neoadjuvant Gemcitabine Plus Nab-paclitaxel vs mFOLFIRINOX at 5 years. Started Dec 2014; status: terminated.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02241551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241551.